175 related articles for article (PubMed ID: 35075288)
1. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
Magrin E; Semeraro M; Hebert N; Joseph L; Magnani A; Chalumeau A; Gabrion A; Roudaut C; Marouene J; Lefrere F; Diana JS; Denis A; Neven B; Funck-Brentano I; Negre O; Renolleau S; Brousse V; Kiger L; Touzot F; Poirot C; Bourget P; El Nemer W; Blanche S; Tréluyer JM; Asmal M; Walls C; Beuzard Y; Schmidt M; Hacein-Bey-Abina S; Asnafi V; Guichard I; Poirée M; Monpoux F; Touraine P; Brouzes C; de Montalembert M; Payen E; Six E; Ribeil JA; Miccio A; Bartolucci P; Leboulch P; Cavazzana M
Nat Med; 2022 Jan; 28(1):81-88. PubMed ID: 35075288
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
[TBL] [Abstract][Full Text] [Related]
3. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
4. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
5. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF
Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.
Boulad F; Maggio A; Wang X; Moi P; Acuto S; Kogel F; Takpradit C; Prockop S; Mansilla-Soto J; Cabriolu A; Odak A; Qu J; Thummar K; Du F; Shen L; Raso S; Barone R; Di Maggio R; Pitrolo L; Giambona A; Mingoia M; Everett JK; Hokama P; Roche AM; Cantu VA; Adhikari H; Reddy S; Bouhassira E; Mohandas N; Bushman FD; Rivière I; Sadelain M
Nat Med; 2022 Jan; 28(1):63-70. PubMed ID: 34980909
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.
Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G
Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
9. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients.
Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C
Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
[TBL] [Abstract][Full Text] [Related]
11. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
Kanter J; Walters MC; Krishnamurti L; Mapara MY; Kwiatkowski JL; Rifkin-Zenenberg S; Aygun B; Kasow KA; Pierciey FJ; Bonner M; Miller A; Zhang X; Lynch J; Kim D; Ribeil JA; Asmal M; Goyal S; Thompson AA; Tisdale JF
N Engl J Med; 2022 Feb; 386(7):617-628. PubMed ID: 34898139
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
13. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.
Payen E; Leboulch P
Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
[TBL] [Abstract][Full Text] [Related]
15. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy in a Patient with Sickle Cell Disease.
Ribeil JA; Hacein-Bey-Abina S; Payen E; Magnani A; Semeraro M; Magrin E; Caccavelli L; Neven B; Bourget P; El Nemer W; Bartolucci P; Weber L; Puy H; Meritet JF; Grevent D; Beuzard Y; Chrétien S; Lefebvre T; Ross RW; Negre O; Veres G; Sandler L; Soni S; de Montalembert M; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2017 Mar; 376(9):848-855. PubMed ID: 28249145
[TBL] [Abstract][Full Text] [Related]
18. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia.
Hongeng S; Anurathapan U; Songdej D; Phuphuakrat A; Jongrak K; Parsons G; Deary B; Bonner M; Veres G; Asmal M
Blood Adv; 2021 Jul; 5(13):2701-2706. PubMed ID: 34196676
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
Persons DA
Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
